Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Jul 14;20(26):8377-92.
doi: 10.3748/wjg.v20.i26.8377.

Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment

Nathalie C Leite  1 , Cristiane A Villela-Nogueira  1 , Claudia R L Cardoso  1 , Gil F Salles  1
Affiliations
Review

Non-alcoholic fatty liver disease and diabetes: from physiopathological interplay to diagnosis and treatment

Nathalie C Leite et al. World J Gastroenterol. .

Abstract

Non-alcoholic fatty liver disease (NAFLD) is highly prevalent in patients with diabetes mellitus and increasing evidence suggests that patients with type 2 diabetes are at a particularly high risk for developing the progressive forms of NAFLD, non-alcoholic steatohepatitis and associated advanced liver fibrosis. Moreover, diabetes is an independent risk factor for NAFLD progression, and for hepatocellular carcinoma development and liver-related mortality in prospective studies. Notwithstanding, patients with NAFLD have an elevated prevalence of prediabetes. Recent studies have shown that NAFLD presence predicts the development of type 2 diabetes. Diabetes and NAFLD have mutual pathogenetic mechanisms and it is possible that genetic and environmental factors interact with metabolic derangements to accelerate NAFLD progression in diabetic patients. The diagnosis of the more advanced stages of NAFLD in diabetic patients shares the same challenges as in non-diabetic patients and it includes imaging and serological methods, although histopathological evaluation is still considered the gold standard diagnostic method. An effective established treatment is not yet available for patients with steatohepatitis and fibrosis and randomized clinical trials including only diabetic patients are lacking. We sought to outline the published data including epidemiology, pathogenesis, diagnosis and treatment of NAFLD in diabetic patients, in order to better understand the interplay between these two prevalent diseases and identify the gaps that still need to be fulfilled in the management of NAFLD in patients with diabetes mellitus.

Keywords: Diabetes mellitus; Diagnosis; Non-alcoholic fatty liver disease; Pathogenesis; Treatment.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Pivotal role of insulin resistance in non-alcoholic fatty liver disease pathophysiology. ↓: Decrease; ↑: Increase. FFA: Free fatty acids; DM: Diabetes mellitus; NAFLD: Non-alcoholic fatty liver disease.
Figure 2
Figure 2
Main physiopathological mechanisms influencing non-alcoholic fatty liver disease. Progression to non-alcoholic steatohepatitis and fibrosis. ↓: Decrease; ↑: Increase. NASH: Non-alcoholic steatohepatitis; FFA: Free fatty acids.
See this image and copyright information in PMC

References

    1. Younossi ZM, Gramlich T, Matteoni CA, Boparai N, McCullough AJ. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004;2:262–265. - PubMed
    1. Trombetta M, Spiazzi G, Zoppini G, Muggeo M. Review article: type 2 diabetes and chronic liver disease in the Verona diabetes study. Aliment Pharmacol Ther. 2005;22 Suppl 2:24–27. - PubMed
    1. Targher G, Bertolini L, Padovani R, Rodella S, Tessari R, Zenari L, Day C, Arcaro G. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care. 2007;30:1212–1218. - PubMed
    1. Leite NC, Salles GF, Araujo AL, Villela-Nogueira CA, Cardoso CR. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 2009;29:113–119. - PubMed
    1. Prashanth M, Ganesh HK, Vima MV, John M, Bandgar T, Joshi SR, Shah SR, Rathi PM, Joshi AS, Thakkar H, et al. Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. J Assoc Physicians India. 2009;57:205–210. - PubMed

Publication types

MeSH terms